Ensysce Biosciences (ENSC) Current Assets (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Current Assets of $7.2 million for Q4 2025, up 35.56% year-over-year from $5.3 million in Q4 2024, and up 147.42% quarter-over-quarter from $2.9 million in Q3 2025.
Ensysce Biosciences (ENSC) Current Assets (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Current Assets for 9 consecutive years, with $7.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets rose 35.56% year-over-year to $7.2 million; the TTM figure through Dec 2025 stood at $7.2 million (up 35.56% YoY), while the FY2025 annual figure was $7.2 million, up 35.56% from the prior year.
- Current Assets rose to $7.2 million in Q4 2025 per ENSC's latest filing, from $2.9 million in the prior quarter.
- Across five years, Current Assets topped out at $15.7 million in Q4 2021 and bottomed at $228213.0 in Q1 2021.
- Historically, Current Assets has averaged $6.0 million across 5 years, with a median of $5.3 million in 2022.
- Annual changes were most pronounced in 2021 — Current Assets jumped 8662.1% — and 2023, when it plunged 71.09%.
- Ensysce Biosciences' Current Assets stood at $15.7 million in 2021, then plunged by 66.17% to $5.3 million in 2022, then tumbled by 56.81% to $2.3 million in 2023, then surged by 133.51% to $5.3 million in 2024, then soared by 35.56% to $7.2 million in 2025.
- Business Quant data shows ENSC's Current Assets at $7.2 million in Q4 2025, $2.9 million in Q3 2025, and $5.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 7.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.25 Mn |
| Sep 30, 2025 | 2.93 Mn |
| Jun 30, 2025 | 5.28 Mn |
| Mar 31, 2025 | 4.40 Mn |
| Dec 31, 2024 | 5.34 Mn |
| Sep 30, 2024 | 9.09 Mn |
| Jun 30, 2024 | 2.46 Mn |
| Mar 31, 2024 | 4.70 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Sep 30, 2023 | 2.76 Mn |
| Jun 30, 2023 | 5.86 Mn |
| Mar 31, 2023 | 3.37 Mn |
| Dec 31, 2022 | 5.30 Mn |
| Sep 30, 2022 | 7.66 Mn |
| Jun 30, 2022 | 7.19 Mn |
| Mar 31, 2022 | 11.66 Mn |
| Dec 31, 2021 | 15.66 Mn |
| Sep 30, 2021 | 8.92 Mn |
| Jun 30, 2021 | 8.36 Mn |
| Mar 31, 2021 | 228,213.00 |